Source: Barron's
Gilead (GILD) reports Q2 earnings July 30th. Analysts expect revenue of $5.51 billion and EPS of $1.72. The revenue estimate implies 4% growth sequentially. Investors should focus on the following key items:
HCV Could Show Signs Of Life
Gilead has experienced a steady decline in revenue. A sequential increase in its top line could energize bulls. The question remains, can the company maintain its momentum? Last quarter Gilead generated product sales of $5.2 billion, down 8% sequentially.
HCV had been in free fall in previous quarters. In Q1, its revenue actually